Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies.
Based on its selective cell surface expression in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), receptor tyrosine kinase ROR1 has recently emerged as a promising target for therapeutic monoclonal antibodies (mAbs). To further assess the suitability of ROR1 for targeted therapy o...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3115963?pdf=render |
id |
doaj-6f239d23702e46eeb452a110423a5022 |
---|---|
record_format |
Article |
spelling |
doaj-6f239d23702e46eeb452a110423a50222020-11-25T01:28:40ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-0166e2101810.1371/journal.pone.0021018Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies.Jiahui YangSivasubramanian BaskarKa Yin KwongMichael G KennedyAdrian WiestnerChristoph RaderBased on its selective cell surface expression in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), receptor tyrosine kinase ROR1 has recently emerged as a promising target for therapeutic monoclonal antibodies (mAbs). To further assess the suitability of ROR1 for targeted therapy of CLL and MCL, a panel of mAbs was generated and its therapeutic utility was investigated.A chimeric rabbit/human Fab library was generated from immunized rabbits and selected by phage display. Chimeric rabbit/human Fab and IgG1 were investigated for their capability to bind to human and mouse ROR1, to mediate antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and internalization, and to agonize or antagonize apoptosis using primary CLL cells from untreated patients as well as MCL cell lines. A panel of mAbs demonstrated high affinity and specificity for a diverse set of epitopes that involve all three extracellular domains of ROR1, are accessible on the cell surface, and mediate internalization. The mAb with the highest affinity and slowest rate of internalization was found to be the only mAb that mediated significant, albeit weak, ADCC. None of the mAbs mediated CDC. Alone, they did not enhance or inhibit apoptosis.Owing to its relatively low cell surface density, ROR1 may be a preferred target for armed rather than naked mAbs. Provided is a panel of fully sequenced and thoroughly characterized anti-ROR1 mAbs suitable for conversion to antibody-drug conjugates, immunotoxins, chimeric antigen receptors, and other armed mAb entities for preclinical and clinical studies.http://europepmc.org/articles/PMC3115963?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jiahui Yang Sivasubramanian Baskar Ka Yin Kwong Michael G Kennedy Adrian Wiestner Christoph Rader |
spellingShingle |
Jiahui Yang Sivasubramanian Baskar Ka Yin Kwong Michael G Kennedy Adrian Wiestner Christoph Rader Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. PLoS ONE |
author_facet |
Jiahui Yang Sivasubramanian Baskar Ka Yin Kwong Michael G Kennedy Adrian Wiestner Christoph Rader |
author_sort |
Jiahui Yang |
title |
Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. |
title_short |
Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. |
title_full |
Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. |
title_fullStr |
Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. |
title_full_unstemmed |
Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. |
title_sort |
therapeutic potential and challenges of targeting receptor tyrosine kinase ror1 with monoclonal antibodies in b-cell malignancies. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2011-01-01 |
description |
Based on its selective cell surface expression in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), receptor tyrosine kinase ROR1 has recently emerged as a promising target for therapeutic monoclonal antibodies (mAbs). To further assess the suitability of ROR1 for targeted therapy of CLL and MCL, a panel of mAbs was generated and its therapeutic utility was investigated.A chimeric rabbit/human Fab library was generated from immunized rabbits and selected by phage display. Chimeric rabbit/human Fab and IgG1 were investigated for their capability to bind to human and mouse ROR1, to mediate antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and internalization, and to agonize or antagonize apoptosis using primary CLL cells from untreated patients as well as MCL cell lines. A panel of mAbs demonstrated high affinity and specificity for a diverse set of epitopes that involve all three extracellular domains of ROR1, are accessible on the cell surface, and mediate internalization. The mAb with the highest affinity and slowest rate of internalization was found to be the only mAb that mediated significant, albeit weak, ADCC. None of the mAbs mediated CDC. Alone, they did not enhance or inhibit apoptosis.Owing to its relatively low cell surface density, ROR1 may be a preferred target for armed rather than naked mAbs. Provided is a panel of fully sequenced and thoroughly characterized anti-ROR1 mAbs suitable for conversion to antibody-drug conjugates, immunotoxins, chimeric antigen receptors, and other armed mAb entities for preclinical and clinical studies. |
url |
http://europepmc.org/articles/PMC3115963?pdf=render |
work_keys_str_mv |
AT jiahuiyang therapeuticpotentialandchallengesoftargetingreceptortyrosinekinaseror1withmonoclonalantibodiesinbcellmalignancies AT sivasubramanianbaskar therapeuticpotentialandchallengesoftargetingreceptortyrosinekinaseror1withmonoclonalantibodiesinbcellmalignancies AT kayinkwong therapeuticpotentialandchallengesoftargetingreceptortyrosinekinaseror1withmonoclonalantibodiesinbcellmalignancies AT michaelgkennedy therapeuticpotentialandchallengesoftargetingreceptortyrosinekinaseror1withmonoclonalantibodiesinbcellmalignancies AT adrianwiestner therapeuticpotentialandchallengesoftargetingreceptortyrosinekinaseror1withmonoclonalantibodiesinbcellmalignancies AT christophrader therapeuticpotentialandchallengesoftargetingreceptortyrosinekinaseror1withmonoclonalantibodiesinbcellmalignancies |
_version_ |
1725100306400804864 |